ProjectUpdated on 3 September 2025
Trophy Life Technology
Business Development Officer at InnoHK Centre for Translational Stem Cell Biology
Hong Kong, China (Hong Kong)
About
Trophy Life Tech accelerates antiviral innovation through its proprietary placenta-like stem cell platform (TSC-STB), enabling rapid and accurate discovery of novel antiviral candidates and development of effective antiviral drugs and health products.
Why Trophy Life
•Proprietary stem cell platform facilitates fast, cost-effective, and highly sensitive antiviral drug screening
•Supports development of broad-spectrum antiviral drugs, supplements, and healthcare products tailored to diverse viral threats
•Unique placenta-like stem cell model mimics human viral infection dynamics, enabling precise efficacy and safety testing
Our advanced platform empowers pharma and biotech partners to overcome traditional drug discovery challenges with scalable, validated cellular models.
Project Location
- China (Hong Kong)
Project Format
- Public-Private Partnership Project
ESG (Environmental, Social, and Governance)
- No
Project Stage
- Project Planning
Main Project Sector
- Technology
Technology
- Bio-Tech
- Health Technology
Total Project Value
- 500,000 USD or Below
Investment Capital Required
- 1,000,001 to 2,500,000 USD
Interested Format of Cooperation
- Joint Venture
- Open for Negotiation
- Requisition of Service
- R&D Cooperation
Preferred Financing Model
- Open for negotiation
Previous Funding Stage
- Seed & Pre-Series
Main Service(s) Required
- Financial Services
- Professional Services
Organisation
InnoHK Centre for Translational Stem Cell Biology
Hong Kong Science and Technology Park, China (Hong Kong)
Similar opportunities
Project
- No
- None
- Bio-Tech
- Technology
- Joint Venture
- R&D Cooperation
- Project Planning
- Health Technology
- Financial Services
- 500,000 USD or Below
- Open for Negotiation
- Open for negotiation
- Professional Services
- 1,000,001 to 2,500,000 USD
- Public-Private Partnership Project
Daisy Tan
Business Development Officer at InnoHK Centre for Translational Stem Cell Biology
Hong Kong, China (Hong Kong)
Project
Single Cell Drug Screening AI Platform
- Yes
- None
- Equity
- Bio-Tech
- Technology
- Private Project
- R&D Cooperation
- Open for negotiation
- Professional Services
- Minority Shareholdings
- 2,500,001 to 5,000,000 USD
- 1,000,001 to 2,500,000 USD
- Feasibility Study Completed
- Public–private partnership / Concession
Marco Suen
Founder & CEO at Provectus Therapeutics Limited
Hong Kong, China (Hong Kong)
Project
- No
- Bio-Tech
- Operations
- Technology
- Private Project
- Seed & Pre-Series
- Medical Technology
- Financial Services
- Open for Negotiation
- Open for negotiation
- Professional Services
- 500,001 to 1,000,000 USD
- 1,000,001 to 2,500,000 USD
Daisy Tan
Business Development Officer at InnoHK Centre for Translational Stem Cell Biology
Hong Kong, China (Hong Kong)